Federal Government Solicits Proposals for Medical Marijuana Cultivation
Exclusive license has been granted to Univ of Mississippi for more than 40 yearsWashington, D.C. -- The federal Department of Health and
Human Services (HHS) issued a Request for Proposals (RFP) last week for
the “Production, Analysis, & Distribution of Cannabis &
Marijuana Cigarettes.” Although the government has issued an exclusive
contract to the University of Mississippi for more than 40 years, the
National Institute on Drug Abuse (NIDA) is allegedly seeking
competitive applications to "grow, harvest, analyze, store and
distribute" cannabis (marijuana) "on large and small scales." The RFP
also seeks applicants that can "extract cannabis to obtain purified
phytocannabinoids," including tetrahydrocannabinol, otherwise known as
THC, "prepare marijuana cigarettes and related products," and
"distribute
marijuana, marijuana cigarettes and cannabinoids, and other related
products for research and other Government programs." The recent RFP is
similar to solicitations that are issued every five years by HHS.
Proposals are due on or about October 9, 2009.
"The bidding process for the production of research-grade cannabis has
not really been as competitive as the government would have us
believe," said
Caren Woodson, Government Affairs Director with Americans for Safe
Access (ASA), a nationwide medical marijuana advocacy organization
pushing for expanded research. "The 40-year monopoly on cannabis
production points to government duplicity that has resulted in a
stranglehold on research in this country."
This RFP process comes only 7 months after the Drug Enforcement
Administration (DEA) rejected an application by botany professor Lyle
Craker from the University of Massachusetts at Amherst to be an
additional producer of cannabis. The rejection followed a years-long
appeals process and ignored the recommendations of the DEA's own
Administrative Law Judge, Mary Ellen Bittner, who issued an 87-page
ruling in February of 2007, concluding that expanded medical marijuana
research was "in the public interest." Judge Bittner also concluded
that the quantity, quality and repeatability of the single-source
supply of marijuana from the University of Mississippi was of
inadequate.
In April, ASA issued a White Paper on the government's obstruction to
medical marijuana research, exposing the cozy relationship between NIDA
and the University of Mississippi's Marijuana Project Director Dr.
Mahmoud ElSohly. The report also details the government's double
standard on medical marijuana with its support of
synthetically-produced pharmaceuticals while opposing the more
available, but unpatentable whole-plant marijuana. The current position
of HHS, which is being legally challenged by ASA in federal court, is
that marijuana "has no currently accepted medical use in treatment in
the United States." Yet, in 2005, during testimony before Judge
Bittner, NIDA Director Dr. Eric Voth testified that indeed, "there is
evidence on the potential
medical use of various cannabinoids (the individual components found in
the
cannabis plant)." The currently available synthetically-derived sources
of cannabis, Marinol and Cesamet, are inferior to whole-plant marijuana
according to hundreds of medical marijuana patients who have tried both.
Adding to the government's seemingly hypocritical position on medical
marijuana is the requirement that RFP applicants be able to produce and
distribute marijuana cigarettes to participants in the Compassionate
Investigational New Drug (IND) program. The IND program, which was
started in 1978, regularly distributes medical marijuana to its four
remaining patients (the program was suspended in 1991 by G.H. Bush).
"How can the federal government continue to distribute marijuana to
seriously ill patients and yet maintain that it has no medical value?"
questions Woodson. "The federal government also chooses to overlook
reams of scientific studies from inside the U.S. and throughout the
world, which unquestionably illustrate the medical efficacy of
marijuana."
HHS is not the only government entity that is licensing the production
of medical marijuana. The State governments of New Mexico and Rhode
Island, as well as local governments in California and Montana, have
either implemented
such programs or will do so soon. These nascent production and
distribution
programs are being implemented in the absence of any comprehensive plan
by the federal government to provide safe access to medical marijuana
for the hundreds of thousands of patients in the U.S. who would benefit
from it.
Further information:
Request
for Proposals on the production and distribution of medical marijuana:
https://www.fbo.gov/index?s=opportunity&mode=form&id=2f734e46a74d477e37ac07798c08a3ae&tab=core&_cview=0&cck=1&au=&ck=
2007 Ruling by DEA Judge Mary Ellen Bittner:
http://AmericansForSafeAccess.org/downloads/Craker_Ruling.pdf
ASA White Paper on the federal government obstruction to medical
marijuana research:
http://AmericansForSafeAccess.org/downloads/Research_Obstruction_Report.pdf


Printer Safe Version
Site Map
Link to Us